In terms of pipeline development, the company reported positive results from the China bridging study of KarXT for schizophrenia and promising Phase 1 data for ZL-1310 in small cell lung cancer. Zai ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS ...
Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...
Bristol-Myers Squibb entered the schizophrenia treatment market through last year's acquisition of biopharma firm Karuna ...
BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
The drug, previously called KarXT, is an oral medication for the treatment of schizophrenia in adults. Cobenfy introduces a fundamentally new approach to treating schizophrenia by selectively ...
Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback